Back to search

Article

A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)

2024-04-04

Abstract excerpt

<h4>Background</h4> Influenza A results in significant morbidity and mortality. VIR-2482, an engineered human monoclonal antibody with extended half-life, targets a highly conserved epitope on the stem region of influenza A hemagglutinin, and may protect against seasonal and pandemic influenza. <h4>Methods</h4> This double-blind, randomized, placebo-controlled, phase 2 study examined the safety and efficacy of VIR...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4ebcc7e6-b3d8-56e4-bbe0-8f6340fc0d87
DOI
10.1101/2024.04.03.24305209
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)DOI 10.1101/2024.04.03.24305209
Select a neighboring publication to make it the new centre.